Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luc Rochette

Showing results (71-80 of 168) with videos related to

Pageof 17
Sort By:
Journal of Cardiovascular Pharmacology|December 25, 2002
ETA, mixed ETA/ETB receptor antagonists, and protein kinase C inhibitor prevent acute hypoxic pulmonary vasoconstriction: influence of potassium channelsFrançoise Goirand, Marc Bardou, Pascal Guerard, et al.
Vascular Pharmacology|June 14, 2006
Dissociation between vascular oxidative stress and cardiovascular function in Wistar Kyoto and spontaneously hypertensive ratsPierre Sicard, Alexandra Oudot, Jean-Claude Guilland, et al.
Trends in Pharmacological Sciences|April 22, 2015
Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanismsLuc Rochette, Charles Guenancia, Aurélie Gudjoncik, et al.
Fundamental & Clinical Pharmacology|March 30, 2007
A peroxynitrite decomposition catalyst: FeTPPS confers cardioprotection during reperfusion after cardioplegic arrest in a working isolated rat heart modelBenjamin Lauzier, Pierre Sicard, Olivier Bouchot, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|November 15, 2006
The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatinZo Rakotoniaina, Pascal Guerard, Frederic Lirussi, et al.
European Journal of Pharmacology|September 16, 2006
Tubulin ligands suggest a microtubule-NADPH oxidase relationship in postischemic cardiomyocytesLisa Devillard, David Vandroux, Cindy Tissier, et al.
International Journal of Molecular Sciences|April 15, 2020
Anti-Aging Effects of GDF11 on SkinLuc Rochette, Loubna Mazini, Alexandre Meloux, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|June 11, 2008
Celecoxib but not the combination of celecoxib+atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the ratZo Rakotoniaina, Pascal Guerard, Frédéric Lirussi, et al.
Molecular Nutrition & Food Research|June 27, 2024
Short-Term Postnatal Overfeeding Induces Long-Lasting Cardiometabolic Syndrome in Mature and Old Mice Associated with Increased Sensitivity to Myocardial InfarctionEve Rigal, Marie Josse, Camille Greco, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|August 10, 2006
The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOSPascal Guerard, Zo Rakotoniaina, Françoise Goirand, et al.
Pageof 17

Showing results (71-80 of 168) with videos related to

Sort By:
Pageof 17
Journal of Cardiovascular Pharmacology|December 25, 2002
ETA, mixed ETA/ETB receptor antagonists, and protein kinase C inhibitor prevent acute hypoxic pulmonary vasoconstriction: influence of potassium channelsFrançoise Goirand, Marc Bardou, Pascal Guerard, et al.
Vascular Pharmacology|June 14, 2006
Dissociation between vascular oxidative stress and cardiovascular function in Wistar Kyoto and spontaneously hypertensive ratsPierre Sicard, Alexandra Oudot, Jean-Claude Guilland, et al.
Trends in Pharmacological Sciences|April 22, 2015
Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanismsLuc Rochette, Charles Guenancia, Aurélie Gudjoncik, et al.
Fundamental & Clinical Pharmacology|March 30, 2007
A peroxynitrite decomposition catalyst: FeTPPS confers cardioprotection during reperfusion after cardioplegic arrest in a working isolated rat heart modelBenjamin Lauzier, Pierre Sicard, Olivier Bouchot, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|November 15, 2006
The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatinZo Rakotoniaina, Pascal Guerard, Frederic Lirussi, et al.
European Journal of Pharmacology|September 16, 2006
Tubulin ligands suggest a microtubule-NADPH oxidase relationship in postischemic cardiomyocytesLisa Devillard, David Vandroux, Cindy Tissier, et al.
International Journal of Molecular Sciences|April 15, 2020
Anti-Aging Effects of GDF11 on SkinLuc Rochette, Loubna Mazini, Alexandre Meloux, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|June 11, 2008
Celecoxib but not the combination of celecoxib+atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the ratZo Rakotoniaina, Pascal Guerard, Frédéric Lirussi, et al.
Molecular Nutrition & Food Research|June 27, 2024
Short-Term Postnatal Overfeeding Induces Long-Lasting Cardiometabolic Syndrome in Mature and Old Mice Associated with Increased Sensitivity to Myocardial InfarctionEve Rigal, Marie Josse, Camille Greco, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|August 10, 2006
The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOSPascal Guerard, Zo Rakotoniaina, Françoise Goirand, et al.
Pageof 17